Retatrutide First Week Checklist — Day-by-Day UAE Research Protocol

Why the First Seven Days Define the Entire Retatrutide Research Arc

Retatrutide is the first GIP/GLP-1/glucagon triple-agonist to demonstrate substantial efficacy in a rigorously controlled human trial. The Jastreboff et al. 2023 NEJM paper — the foundational Phase 2 publication — reported mean body weight reductions of up to 17.5% at 24 weeks across dose cohorts, with a statistically clear dose-response relationship beginning at the lowest tested range. That dose-response arc does not start at week four. It starts on day one, with how precisely and consistently you structure the initiation phase of the protocol.

Research teams operating across Dubai, Abu Dhabi, Sharjah, and the wider UAE face a specific combination of environmental and logistical variables that researchers in cooler, less logistically dynamic markets simply do not encounter. Ambient temperatures exceeding 42°C in summer months, refrigeration reliability in mixed-use commercial and residential settings, discreet courier access across densely populated areas like Business Bay and JBR, and supply continuity for a compound that has seen surging global research interest since the TRIUMPH Phase 3 readouts — all of these are real protocol design considerations here. This checklist is built specifically for those conditions, not adapted from a generic European or North American lab template.

Everything in this document is framed for research and laboratory use only. Nothing here constitutes medical advice, clinical guidance, or a recommendation for human consumption. Retatrutide supplied by REVIVE LAB UAE is a research peptide supplied to qualified researchers and laboratory professionals. If you are seeking treatment for any health condition, consult a licensed medical professional.

Before Day 1: The Pre-Protocol Preparation Checklist

The most common source of noise in a retatrutide research dataset is not the peptide — it is the preparation environment. Inconsistent reconstitution, poor baseline documentation, and improper storage in UAE conditions all introduce variables that make your week-one data difficult to interpret and your titration decisions harder to justify. Before your order from REVIVE LAB UAE arrives, have the following assembled and verified.

Equipment and Consumables

• Bacteriostatic water (BW), pharmaceutical grade — 0.9% benzyl alcohol preserved, typically available in 10ml or 30ml vials from compounding pharmacies. Do not substitute plain sterile water for injection if your protocol design requires multi-day stability from a reconstituted vial. BW's preservative component meaningfully extends post-reconstitution usability in research contexts.
• Insulin syringes, 1ml capacity, 28–31G — low dead-volume format. Available from major UAE pharmacy chains including those in Al Barsha, Marina Walk, and Business Bay towers. Sub-milligram precision in the lower research dose ranges requires this calibre of syringe; standard 3ml or 5ml syringes introduce unacceptable measurement error at these volumes.
• Alcohol swabs, 70% isopropyl — for vial septum sterilisation before every draw. Non-negotiable in the UAE environment, where moving between air-conditioned labs and ambient outdoor temperatures above 40°C creates condensation on surfaces, including vial caps.
• A dedicated refrigeration unit maintaining 2–8°C — a calibrated mini-fridge, not a domestic door shelf. See the Day 2–3 storage section below for specific Dubai-climate guidance. Lyophilised retatrutide is stable at ambient room temperature prior to reconstitution, but post-reconstitution requires consistent cold storage.
• Research logbook or structured spreadsheet — configured before day 1, not improvised after. Fields should include: date, time, vial ID, calculated concentration, volume drawn, administration route, and all primary outcome metrics relevant to your study design.
• A precision timer — for consistent protocol timing. If your research design calls for weekly administration, the inter-dose interval needs to be held constant across weeks to avoid timing confounds in your longitudinal data.

Baseline Documentation — Day 0

The day before protocol start is Day 0. Document all primary outcome metrics now, under identical conditions to how you will measure them throughout the protocol. In the Jastreboff 2023 NEJM trial design, the relevant measurement domains included body weight (fasted, morning, standardised scale), waist circumference, fasting plasma glucose, fasting insulin, lipid panel, and blood pressure. Your specific research design will determine which of these apply. Without a clean Day 0 baseline, week-one data has no reference point and your protocol loses interpretive value from the outset.

Day 1: Reconstitution, Concentration Calculation, and Protocol Start

Reconstitution Step-by-Step

REVIVE LAB UAE supplies retatrutide as a lyophilised powder in 5mg and 10mg vials. The lyophilised form ships stable at ambient temperature, which is why same-day courier delivery across Dubai — including Marina, JBR, Downtown, DIFC, Business Bay, and the Palm — does not compromise peptide integrity even during peak UAE summer, when vehicle cabin temperatures can spike far above ambient. Once reconstituted, however, the compound requires immediate refrigeration and should be used within a protocol-defined stability window.

1. Allow the sealed, unopened vial to reach ambient room temperature if it has been stored in a cooler or fridge for any reason. Temperature normalisation before adding BW reduces thermal shock to the lyophilised cake and minimises particulate formation in the resulting solution.
2. Swab the vial septum with a 70% isopropyl alcohol wipe. Allow 30 full seconds to air-dry before inserting a needle. Residual alcohol on the septum can enter the vial and affect peptide stability.
3. Draw your calculated volume of bacteriostatic water into the insulin syringe. Confirm the volume before insertion.
4. Insert the needle at a slight angle through the septum and inject the BW slowly down the inner glass wall of the vial — not directly onto the lyophilised powder cake. Wall-directed injection prevents foaming and avoids mechanical shear stress on the peptide chains, both of which can reduce effective concentration.
5. Do not shake. Gently swirl or roll the vial between your palms until the powder fully dissolves. The resulting solution should be clear and essentially colourless. Any cloudiness, visible particulate, or discolouration is a discard signal — do not use the vial and contact REVIVE LAB UAE for replacement.
6. Label the vial immediately with the date of reconstitution, the volume of BW added, and the resulting concentration in mg/ml. Refrigerate at 2–8°C and return it to the back of the fridge — not the door shelf.

Concentration Calculation for Research Titration Ranges

The Jastreboff 2023 NEJM Phase 2 trial used escalating dose cohorts that, in research contexts, correspond to approximately 2mg, 4mg, and 8mg reference points. Selecting your reconstitution volume on Day 1 determines how convenient your syringe draws will be across the titration schedule. The table below covers the two most practical configurations for REVIVE LAB UAE's 5mg and 10mg vials.

For week-one protocols using the 2mg research starting range, the 5mg vial reconstituted at 2mg/ml gives the cleanest syringe arithmetic: 1.0ml draws on a standard 1ml insulin syringe, leaving no ambiguity about partial markings. Document your chosen configuration in your research log before the first draw on Day 1.

Days 2–3: Storage Verification, Early-Phase Data Capture, and Environment Logging

The Dubai Storage Problem — and How to Solve It

On Day 2, before you do anything else with your protocol, verify your reconstituted vial storage conditions. This is not a formality. In Dubai apartments and offices — particularly in Marina, JBR, Al Quoz industrial units, and Business Bay towers with variable HVAC systems — domestic refrigerators commonly cycle in ways that compromise peptide stability. The two failure modes are temperature spiking (fridge door left open during frequent access in a warm kitchen) and temperature dropping below 0°C when the thermostat is set too aggressively. Both degrade retatrutide. Repeated freeze-thaw cycles are among the most damaging variables in peptide research storage, producing aggregation and reduced bioactivity that no amount of careful dosing protocol can correct.

Practical solution for Dubai-based labs: dedicate a small, independently controlled cooler or undercounter fridge solely to research peptide storage. Set it at 4°C and do not share it with food. If you are operating from a Palm villa, a Sharjah warehouse lab, or an Abu Dhabi research facility with reliable climate control, a standard laboratory fridge is straightforward. If you are running a leaner operation from a Business Bay serviced office, a 12V Peltier cooler with a battery backup is a pragmatic and cost-effective alternative that eliminates the domestic-fridge variability problem entirely.

Day 2–3 Data Collection Targets

The first 48 hours of a retatrutide protocol are the highest-signal window for early response characterisation. The GIP/GLP-1/glucagon triple-agonist mechanism acts across multiple receptor pathways simultaneously, and the research literature — including both Jastreboff 2023 and the Eli Lilly TRIUMPH Phase 3 readouts — confirms that early-phase tolerability and initial metabolic signalling establish the trajectory the rest of the protocol will follow. Your data collection on Days 2 and 3 should be rigorous even if observed changes appear modest.

• Body weight delta from Day 0 baseline — same conditions, same time, fasted morning measurement. At the 2mg starting reference range, week-one weight changes are typically small, but establishing a clean trendline early is the entire point. Noise in early data propagates through every subsequent comparison.
• Appetite analogue scale reading — if your research design includes subjective appetite quantification, standardise timing rigorously (e.g., 30 minutes before the same meal each day) and use a validated visual analogue scale (VAS). The GLP-1 receptor agonist component of retatrutide produces satiety signalling that is often detectable before weight changes become measurable, making appetite metrics a leading indicator in your dataset.
• Energy intake log — if dietary intake is a tracked variable in your design, Days 2 and 3 are when GLP-1-mediated reductions in caloric intake may first become apparent. Capture this with the same level of precision as your biological markers.
• Adverse signal log — nausea, injection site reaction, gastrointestinal motility changes, and headache are known class effects from the GLP-1 receptor agonist component. They were documented across all cohort arms in both the Phase 2 and Phase 3 programmes. In a research context, these are data points that need structured documentation, not reasons to abandon the protocol without recording.

Days 4–5: Mid-Week Titration Assessment and Protocol Calibration

By Day 4, a properly instrumented research protocol has enough early-phase signal to make an informed decision about the second-week design. The core question is whether the initial reference dose range is producing the expected tolerability and early efficacy signal, and whether any adverse signals logged in Days 2–3 are persisting, resolving, or escalating. This mid-week checkpoint is where protocol calibration decisions are made — not reactively at the end of week one when you have less time to adjust before week-two dosing.

Research Titration Decision Framework

The Jastreboff 2023 NEJM paper used a structured escalation schedule across its dose arms. In research contexts evaluating the 2mg, 4mg, and 8mg reference ranges, the following framework is consistent with published Phase 2 design logic:

The 10mg vial from REVIVE LAB UAE is the more economical and practical choice for multi-week protocols. A single 10mg vial reconstituted at 2mg/ml covers five reference doses at the 2mg starting range — enough for five weeks of weekly-dosing design at that reference level. When moving to the 4mg range, the same vial covers two full weeks with one partial dose remaining. For researchers in Abu Dhabi, Sharjah, or the Northern Emirates placing standing orders, REVIVE LAB UAE's same-day Dubai dispatch with next-morning inter-emirate delivery means stock planning can be done on a week-by-week basis without holding excessive inventory in-lab.

UAE-Specific Environmental Variables to Document at Days 4–5

Research protocols running across UAE calendar periods must account for local environmental variables that affect outcome data interpretability. From May through September, outdoor ambient temperatures regularly exceed 42°C in Dubai, Abu Dhabi, and Sharjah, substantially suppressing voluntary physical activity in free-living study subjects and altering hydration status, basal metabolic rate context, and dietary patterns. If your research design involves free-living human subjects, these environmental contextual variables need to be documented alongside your biological outcome metrics on Days 4 and 5. A protocol that ignores the UAE summer as a confound is a protocol with a significant interpretive gap.

Days 6–7: Week-One Close-Out, Data Review, and Week-Two Preparation

End-of-Week Data Snapshot Protocol

Day 7 is your first structured data close-out point. Pull together every measurement taken since Day 0 and run the following checks before finalising your week-two design:

• Weight delta, Day 0 to Day 7 — in the Jastreboff 2023 cohorts, measurable weight changes at the lowest dose range were modest in week one but established a clear downward trajectory that accelerated through weeks 4–12. A flat or near-flat week-one trendline at the 2mg starting reference range is consistent with published dose-response data. It is not a protocol failure signal — it is expected early-phase behaviour. Do not adjust your titration schedule based on week-one weight data alone.
• Appetite metric delta, Day 0 to Day 7 — GLP-1-mediated appetite signalling typically precedes measurable weight changes by one to three weeks in the published literature. If your research design includes appetite measurement, Day 7 is where you should expect the first clearly distinguishable shift from your Day 0 baseline. A meaningful VAS shift with a flat weight trendline is a normal and interpretable early-phase finding.
• Adverse signal pattern review — review all logged adverse signals for temporal patterns. Nausea clustering at specific times post-dose? Injection site reactions persisting beyond 48 hours? These patterns inform whether your week-two protocol design needs any data capture methodology refinements before dose escalation.
• Reconstituted vial inventory check — how many doses remain from your week-one vial? A 5mg vial reconstituted at 2mg/ml yields 2.5 doses at the 2mg reference range. If week two moves to the 4mg reference range, a fresh 5mg vial covers two full week-two doses with no remainder. Plan your next order to REVIVE LAB UAE at Day 5 or Day 6 — placing the order by 2 PM GST on Day 6 means same-day Dubai delivery or next-morning delivery to Abu Dhabi, Sharjah, and the Northern Emirates, landing in time for a Day-8 week-two start with zero gap in your protocol timeline.

Documenting Your Week-Two Protocol Before Week One Ends

The discipline that separates rigorous research design from ad hoc peptide use is documentation ahead of the decision point, not after it. Before Day 7 ends, your research log should contain a written week-two protocol specification: the planned reference dose range, the administration timing, the full set of monitoring parameters, and the supply quantities required. If your design calls for the 4mg reference range in week two and you are using a 10mg vial from REVIVE LAB UAE reconstituted at 2mg/ml, you have five doses available — more than enough to carry a standard weekly-dosing protocol through weeks two and three with supply to spare. If you are on 5mg vials, order your week-two stock now.

Sourcing Retatrutide in the UAE: What Actually Matters

The UAE research peptide supply landscape has become meaningfully more sophisticated in the past 18 months. Customs clearance for properly classified research compounds is faster and more predictable than most researchers outside the region expect. Courier infrastructure in Dubai — DHL, Aramex, and multiple same-day local services — is genuinely world-class, comparable to or better than London or Singapore for same-day delivery within city bounds. What has remained the genuine friction point is stock availability for high-demand compounds. Retatrutide specifically has seen surging global research interest since both the Jastreboff 2023 NEJM publication and the subsequent Eli Lilly TRIUMPH Phase 3 data readouts, and out-of-stock gaps from suppliers who do not carry deep UAE-facing inventory can disrupt an ongoing protocol at exactly the wrong moment.

REVIVE LAB UAE maintains dedicated in-stock inventory of retatrutide 5mg and 10mg vials specifically to serve UAE-based researchers who cannot absorb a mid-protocol supply gap. All orders ship in discreet, unmarked outer packaging with no indication of contents on the external box — a non-trivial operational detail for researchers working in shared Business Bay office environments, Dubai Science Park clusters, or shared residential accommodation in Al Barsha, JBR, or Al Quoz.

Payment options are practical for the UAE market: cash on delivery (COD) is available across the Emirates, and Binance Pay (USDT TRC20) qualifies for a 5% pre-pay discount for researchers who prefer to settle in advance. WhatsApp order confirmation is the fastest fulfilment path for urgent same-day retatrutide Dubai delivery requests — contact details are on the REVIVE LAB UAE site. For researchers placing recurring monthly orders to cover extended protocols, pre-pay via Binance Pay is the most cost-efficient route at scale.

One point worth stating directly: the combination of in-stock availability, same-day dispatch from Dubai, discreet packaging, and COD payment is not a standard offering from international research peptide suppliers shipping into the UAE. Most international suppliers cannot guarantee same-day delivery to a Business Bay address or a Palm villa. REVIVE LAB UAE can, and for a running research protocol, that logistical reliability is as important as peptide purity.

FAQ

Can I order retatrutide with same-day delivery in Dubai?

Yes. REVIVE LAB UAE dispatches retatrutide orders placed before 2 PM GST with same-day courier delivery across Dubai, including Marina, Business Bay, JBR, DIFC, Downtown, and the Palm Jumeirah. Orders to Abu Dhabi and Sharjah are dispatched same-day with next-morning delivery. Retatrutide is stocked in 5mg and 10mg vials and is supplied for research and laboratory use only.

What vial sizes of retatrutide does REVIVE LAB UAE stock?

REVIVE LAB UAE stocks retatrutide in 5mg and 10mg lyophilised vials. Both sizes are available for immediate dispatch to researchers and laboratory professionals across the UAE. The 10mg vial is the most cost-efficient choice for multi-week research protocols at the 4mg and 8mg reference ranges, covering multiple weekly administrations from a single vial. All supply is for research use only.

Does REVIVE LAB UAE offer cash on delivery for retatrutide in Dubai?

Yes. Cash on delivery (COD) is available for retatrutide orders across Dubai and the wider UAE. Alternatively, payment via Binance Pay (USDT TRC20) qualifies for a 5% pre-pay discount. All orders are shipped in discreet, unmarked outer packaging with no external indication of the contents — this is standard on every REVIVE LAB UAE order, not an optional upgrade.